ID: ALA1950801

Max Phase: Preclinical

Molecular Formula: C19H18N4O5

Molecular Weight: 382.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)[C@H]1NCCN(C(=O)c2ccc(/N=N/c3ccccc3)cc2)[C@H]1C(=O)O

Standard InChI:  InChI=1S/C19H18N4O5/c24-17(23-11-10-20-15(18(25)26)16(23)19(27)28)12-6-8-14(9-7-12)22-21-13-4-2-1-3-5-13/h1-9,15-16,20H,10-11H2,(H,25,26)(H,27,28)/b22-21+/t15-,16+/m0/s1

Standard InChI Key:  OWLCQDZNALVPKV-BQLLGCRXSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 382.38

Molecular Weight (Monoisotopic): 382.1277

AlogP: 2.05

#Rotatable Bonds: 5

Polar Surface Area: 131.66

Molecular Species: ACID

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 2.13

CX Basic pKa: 7.81

CX LogP: -0.05

CX LogD: -3.44

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.68

Np Likeness Score: -0.51

References

1. Irvine MW, Costa BM, Dlaboga D, Culley GR, Hulse R, Scholefield CL, Atlason P, Fang G, Eaves R, Morley R, Mayo-Martin MB, Amici M, Bortolotto ZA, Donaldson L, Collingridge GL, Molnár E, Monaghan DT, Jane DE..  (2012)  Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors.,  55  (1): [PMID:22111545] [10.1021/jm201230z]

Source

Source(1):

• Scientific Literature